These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 34051337)
1. TDO2 knockdown inhibits colorectal cancer progression via TDO2-KYNU-AhR pathway. Zhao L; Wang B; Yang C; Lin Y; Zhang Z; Wang S; Ye Y; Shen Z Gene; 2021 Aug; 792():145736. PubMed ID: 34051337 [TBL] [Abstract][Full Text] [Related]
2. A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer. D'Amato NC; Rogers TJ; Gordon MA; Greene LI; Cochrane DR; Spoelstra NS; Nemkov TG; D'Alessandro A; Hansen KC; Richer JK Cancer Res; 2015 Nov; 75(21):4651-64. PubMed ID: 26363006 [TBL] [Abstract][Full Text] [Related]
3. TDO2 Overexpression Is Associated with Cancer Stem Cells and Poor Prognosis in Esophageal Squamous Cell Carcinoma. Pham QT; Oue N; Sekino Y; Yamamoto Y; Shigematsu Y; Sakamoto N; Sentani K; Uraoka N; Yasui W Oncology; 2018; 95(5):297-308. PubMed ID: 30134247 [TBL] [Abstract][Full Text] [Related]
4. Targeting of neuroblastoma cells through Kynurenine-AHR pathway inhibition. Dos Santos IL; Mitchell M; Nogueira PAS; Lafita-Navarro MC; Perez-Castro L; Eriom J; Kilgore JA; Williams NS; Guo L; Xu L; Conacci-Sorrell M FEBS J; 2024 May; 291(10):2172-2190. PubMed ID: 38431776 [TBL] [Abstract][Full Text] [Related]
5. Tryptophan 2, 3‑dioxygenase promotes proliferation, migration and invasion of ovarian cancer cells. Zhao Y; Tao F; Jiang J; Chen L; Du J; Cheng X; He Q; Zhong S; Chen W; Wu X; Ou R; Xu Y; Tang KF Mol Med Rep; 2021 Jun; 23(6):. PubMed ID: 33846800 [TBL] [Abstract][Full Text] [Related]
7. Long Non-Coding RNA SH3PXD2A-AS1 Promotes Cell Progression Partly Through Epigenetic Silencing P57 and KLF2 in Colorectal Cancer. Ma Z; Peng P; Zhou J; Hui B; Ji H; Wang J; Wang K Cell Physiol Biochem; 2018; 46(6):2197-2214. PubMed ID: 29734178 [TBL] [Abstract][Full Text] [Related]
8. Tryptophan metabolism induced by TDO2 promotes prostatic cancer chemotherapy resistance in a AhR/c-Myc dependent manner. Li F; Zhao Z; Zhang Z; Zhang Y; Guan W BMC Cancer; 2021 Oct; 21(1):1112. PubMed ID: 34657603 [TBL] [Abstract][Full Text] [Related]
9. Ligand independent aryl hydrocarbon receptor inhibits lung cancer cell invasion by degradation of Smad4. Lee CC; Yang WH; Li CH; Cheng YW; Tsai CH; Kang JJ Cancer Lett; 2016 Jul; 376(2):211-7. PubMed ID: 27060206 [TBL] [Abstract][Full Text] [Related]
10. Overexpression of BIRC6 Is a Predictor of Prognosis for Colorectal Cancer. Hu T; Weng S; Tang W; Xue R; Chen S; Cai G; Cai Y; Shen X; Zhang S; Dong L PLoS One; 2015; 10(5):e0125281. PubMed ID: 25933218 [TBL] [Abstract][Full Text] [Related]
11. An Aryl Hydrocarbon Receptor-Mediated Amplification Loop That Enforces Cell Migration in ER-/PR-/Her2- Human Breast Cancer Cells. Novikov O; Wang Z; Stanford EA; Parks AJ; Ramirez-Cardenas A; Landesman E; Laklouk I; Sarita-Reyes C; Gusenleitner D; Li A; Monti S; Manteiga S; Lee K; Sherr DH Mol Pharmacol; 2016 Nov; 90(5):674-688. PubMed ID: 27573671 [TBL] [Abstract][Full Text] [Related]
12. Breakdown of chemo-immune resistance by a TDO2-targeted Pt(IV) prodrug via attenuating endogenous Kyn-AhR-AQP4 metabolic circuity and TLS-promoted genomic instability. Chen F; Xu G; Tian W; Gou S Biochem Pharmacol; 2021 Nov; 193():114785. PubMed ID: 34562469 [TBL] [Abstract][Full Text] [Related]
13. STIP1 knockdown suppresses colorectal cancer cell proliferation, migration and invasion by inhibiting STAT3 pathway. Xia Y; Chen J; Liu G; Huang W; Wei X; Wei Z; He Y Chem Biol Interact; 2021 May; 341():109446. PubMed ID: 33766539 [TBL] [Abstract][Full Text] [Related]
14. Silencing of Girdin suppresses the malignant behavior of colorectal carcinoma cells. Lu J; Zhang L; Zhou H; Du Z; Zhang G Oncol Rep; 2018 Aug; 40(2):887-894. PubMed ID: 29989653 [TBL] [Abstract][Full Text] [Related]
15. Constitutive Expression of the Immunosuppressive Tryptophan Dioxygenase TDO2 in Glioblastoma Is Driven by the Transcription Factor C/EBPβ. Kudo T; Prentzell MT; Mohapatra SR; Sahm F; Zhao Z; Grummt I; Wick W; Opitz CA; Platten M; Green EW Front Immunol; 2020; 11():657. PubMed ID: 32477324 [TBL] [Abstract][Full Text] [Related]
16. p130Cas Is Correlated with EREG Expression and a Prognostic Factor Depending on Colorectal Cancer Stage and Localization Reducing FOLFIRI Efficacy. Kumbrink J; Li P; Pók-Udvari A; Klauschen F; Kirchner T; Jung A Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830244 [TBL] [Abstract][Full Text] [Related]
17. Stemness and immune evasion conferred by the TDO2-AHR pathway are associated with liver metastasis of colon cancer. Miyazaki T; Chung S; Sakai H; Ohata H; Obata Y; Shiokawa D; Mizoguchi Y; Kubo T; Ichikawa H; Taniguchi H; Aoki K; Soga T; Nakagama H; Okamoto K Cancer Sci; 2022 Jan; 113(1):170-181. PubMed ID: 34714577 [TBL] [Abstract][Full Text] [Related]
18. High expression of atonal homolog 8 predicts a poor clinical outcome in patients with colorectal cancer and contributes to tumor progression. Ye M; He Y; Lin H; Yang S; Zhou Y; Zhou L; Zhong J; Lu G; Zheng J; Xue ZX; Cai ZZ Oncol Rep; 2017 May; 37(5):2955-2963. PubMed ID: 28393252 [TBL] [Abstract][Full Text] [Related]
19. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities. Cheong JE; Sun L Trends Pharmacol Sci; 2018 Mar; 39(3):307-325. PubMed ID: 29254698 [TBL] [Abstract][Full Text] [Related]
20. ETV4 plays a role on the primary events during the adenoma-adenocarcinoma progression in colorectal cancer. Fonseca AS; Ramão A; Bürger MC; de Souza JES; Zanette DL; de Molfetta GA; de Araújo LF; de Barros E Lima Bueno R; Aguiar GM; Plaça JR; Alves CP; Dos Santos ARD; Vidal DO; Silva GEB; Panepucci RA; Peria FM; Feres O; da Rocha JJR; Zago MA; Silva WA BMC Cancer; 2021 Mar; 21(1):207. PubMed ID: 33648461 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]